Clinicopathological and molecular features of the 56 cyclin D1−MCLs
| Parameter . | Total, n = 56 . | Cyclin D2+, n = 43 . | Cyclin D3+, n = 9 . | Cyclin E+, n = 4 . | P . |
|---|---|---|---|---|---|
| Median age, y | 65 | 66 | 60 | 75 | .161 |
| Ratio male/female | 2.4/1 | 3.2/1 | 2/1 | 0/1 | .029* |
| Growth pattern (%) | 1 | ||||
| Nodular and/or diffuse | 50/52 (96) | 40/42 (95) | 6/6 (100) | 4/4 (100) | |
| Mantle zone | 2/52 (4) | 2/42 (5) | 0/6 (0) | 0/4 (0) | |
| Morphology (%) | .029* | ||||
| Classical | 43 (81) | 34/40 (85) | 8/9 (89) | 1/4 (25) | |
| Blastoid | 10 (19) | 6/40 (15) | 1/9 (11) | 3/4 (75) | |
| Expression (%) | |||||
| SOX11+ | 56 (100) | 43/43 (100) | 9/9 (100) | 4/4 (100) | 1 |
| CD5+ | 54/55 (98) | 43/43 (100) | 7/8 (88) | 4/4 (100) | .218 |
| CD23− | 47/47 (100) | 36/36 (100) | 7/7 (100) | 4/4 (100) | 1 |
| CD10− | 39/39 (100) | 31/31 (100) | 4/4 (100) | 4/4 (100) | 1 |
| Ig λ light-chain restriction | 20/25 (80) | 15/19 (79) | 3/3 (100) | 2/3 (67) | 1 |
| Ki67 (≥30%) | 24/42 (57) | 18/33 (55) | 2/5 (40) | 4/4 (100) | .153 |
| Median expression (qPCR) | |||||
| CCND2 | 17.0 | 124.8 | 7.0 | 4.8 | <.001* |
| CCND3 | 2.0 | 1.8 | 18.9 | 2.6 | <.001* |
| CCNE1 | 1.0 | 1.1 | 0.9 | 7.6 | .009* |
| CCNE2 | 0.8 | 0.8 | 0.6 | 3.8 | .077 |
| Molecular | |||||
| Median CNA per case | 10 | 9 | 9 | 17 | .098 |
| Chromothripsis (%) | 10/42 (24) | 6/29 (21) | 3/9 (33) | 1/4 (25) | .847 |
| −17p13/TP53 (%) | 8/42 (19) | 8/29 (28) | 0/9 (0) | 0/4 (0) | .144 |
| −11q22/ATM (%) | 14/42 (33) | 9/29 (31) | 5/9 (55) | 0/4 (0) | .140 |
| −9p21/CDKN2A (%) | 20/42 (48) | 14/29 (48) | 2/9 (22) | 4/4 (100) | .033* |
| −13q14/RB1 (%) | 17/42 (40) | 9/29 (31) | 4/9 (44) | 4/4 (100) | .030* |
| +18q (%) | 15/42 (36) | 8/29 (28) | 3/9 (33) | 4/4 (100) | .025* |
| +3q (%) | 23/42 (55) | 18/29 (62) | 3/9 (33) | 2/4 (50) | .378 |
| −1p (%) | 16/42 (38) | 10/29 (34) | 6/9 (67) | 0/4 (0) | .049* |
| Clinical data (%) | |||||
| Treated at diagnosis† | 38/41 (93) | 27/29 (93) | 7/8 (88) | 4/4 (100) | .589 |
| High-dose therapy | 2/41 (5) | 2/29 (7) | — | — | |
| Immunochemotherapy | 25/41 (61) | 18/29 (62) | 3/8 (38) | 4/4 (100) | |
| Other | 11/41 (27) | 7/29 (24) | 4/8 (50) | — | |
| Observation | 3/41 (7) | 2/29 (7) | 1/8 (13) | — | |
| 3-y overall survival, % (95% CI) | 68 (54-86) | 59 (42-83) | 100 (100-100) | 75 (43-100) | .424 |
| Parameter . | Total, n = 56 . | Cyclin D2+, n = 43 . | Cyclin D3+, n = 9 . | Cyclin E+, n = 4 . | P . |
|---|---|---|---|---|---|
| Median age, y | 65 | 66 | 60 | 75 | .161 |
| Ratio male/female | 2.4/1 | 3.2/1 | 2/1 | 0/1 | .029* |
| Growth pattern (%) | 1 | ||||
| Nodular and/or diffuse | 50/52 (96) | 40/42 (95) | 6/6 (100) | 4/4 (100) | |
| Mantle zone | 2/52 (4) | 2/42 (5) | 0/6 (0) | 0/4 (0) | |
| Morphology (%) | .029* | ||||
| Classical | 43 (81) | 34/40 (85) | 8/9 (89) | 1/4 (25) | |
| Blastoid | 10 (19) | 6/40 (15) | 1/9 (11) | 3/4 (75) | |
| Expression (%) | |||||
| SOX11+ | 56 (100) | 43/43 (100) | 9/9 (100) | 4/4 (100) | 1 |
| CD5+ | 54/55 (98) | 43/43 (100) | 7/8 (88) | 4/4 (100) | .218 |
| CD23− | 47/47 (100) | 36/36 (100) | 7/7 (100) | 4/4 (100) | 1 |
| CD10− | 39/39 (100) | 31/31 (100) | 4/4 (100) | 4/4 (100) | 1 |
| Ig λ light-chain restriction | 20/25 (80) | 15/19 (79) | 3/3 (100) | 2/3 (67) | 1 |
| Ki67 (≥30%) | 24/42 (57) | 18/33 (55) | 2/5 (40) | 4/4 (100) | .153 |
| Median expression (qPCR) | |||||
| CCND2 | 17.0 | 124.8 | 7.0 | 4.8 | <.001* |
| CCND3 | 2.0 | 1.8 | 18.9 | 2.6 | <.001* |
| CCNE1 | 1.0 | 1.1 | 0.9 | 7.6 | .009* |
| CCNE2 | 0.8 | 0.8 | 0.6 | 3.8 | .077 |
| Molecular | |||||
| Median CNA per case | 10 | 9 | 9 | 17 | .098 |
| Chromothripsis (%) | 10/42 (24) | 6/29 (21) | 3/9 (33) | 1/4 (25) | .847 |
| −17p13/TP53 (%) | 8/42 (19) | 8/29 (28) | 0/9 (0) | 0/4 (0) | .144 |
| −11q22/ATM (%) | 14/42 (33) | 9/29 (31) | 5/9 (55) | 0/4 (0) | .140 |
| −9p21/CDKN2A (%) | 20/42 (48) | 14/29 (48) | 2/9 (22) | 4/4 (100) | .033* |
| −13q14/RB1 (%) | 17/42 (40) | 9/29 (31) | 4/9 (44) | 4/4 (100) | .030* |
| +18q (%) | 15/42 (36) | 8/29 (28) | 3/9 (33) | 4/4 (100) | .025* |
| +3q (%) | 23/42 (55) | 18/29 (62) | 3/9 (33) | 2/4 (50) | .378 |
| −1p (%) | 16/42 (38) | 10/29 (34) | 6/9 (67) | 0/4 (0) | .049* |
| Clinical data (%) | |||||
| Treated at diagnosis† | 38/41 (93) | 27/29 (93) | 7/8 (88) | 4/4 (100) | .589 |
| High-dose therapy | 2/41 (5) | 2/29 (7) | — | — | |
| Immunochemotherapy | 25/41 (61) | 18/29 (62) | 3/8 (38) | 4/4 (100) | |
| Other | 11/41 (27) | 7/29 (24) | 4/8 (50) | — | |
| Observation | 3/41 (7) | 2/29 (7) | 1/8 (13) | — | |
| 3-y overall survival, % (95% CI) | 68 (54-86) | 59 (42-83) | 100 (100-100) | 75 (43-100) | .424 |
—, no cases; CI, confidence interval; Ig, immunoglobulin.
P < .05 was considered significant. P values were calculated using the Fisher’s exact and Kruskal-Wallis tests for categorical or continuous variables between the 3 groups, respectively.
High-dose therapy includes cytarabine-based immunochemotherapy; immunochemotherapy includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-CHOP–like regimens; and other includes low-dose therapy (alkylating agents alone or in combination) and radiotherapy.